We provide the latest news
from the world of economics and finance
(RTTNews) - Nuvectis Pharma, Inc. (NVCT) said its NXP900, in combination with Osimertinib, showed robust activity in non-small cell lung cancer cell lines. This confirmed data previously published by the research team at Astra Zeneca. The combination reversed resistance to osimertinib versus osimertinib alone.
Also, NXP900 showed potent, single agent, antiproliferative activity in anaplastic lymphoma kinase-resistant NSCLC cells and synergistic effects in combination with alectinib in alectinib sensitive cells. Alectinib is the active ingredient in Alecensa, an ALK inhibitor approved for the treatment of non-small cell lung cancer.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
© 2024 Lime Trading (CY) Ltd
Lime Trading (CY) Ltd is authorised and regulated by the Cyprus Securities and Exchange Commission in accordance with license No.281/15 issued on 25/09/2015. The "Just2Trade" trademark is owned by LimeTrading (CY) Ltd.
Registration Number: HE 341520
Address: Lime Trading (CY) Ltd
Magnum Business Center, Office 4B, Spyrou Kyprianou Avenue 78
Limassol 3076, Cyprus
Disclaimer:
All promotions, materials and information of this website may have applied conditions. Please contact the Company for further details
Trading on financial markets carries risks. The value of the investments can both increase and decrease and the investors may lose all their investment capital. In case of a leveraged product, the loss may be more than the initial capital invested. Detailed information on risks associated with trading on financial markets can be found in General Terms and Conditions for the Provision of Investment Services.